ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
A research study to evaluate the activity of alectinib for the Treatment of pretreated
patients with advanced NSCLC that have confirmed RETrearrangement.